LiquidPlex™ Dx is a targeted gene panel for ctDNA that covers key biomarkers implicated in the most prevalent solid tumors, especially non-small cell lung cancer (NSCLC). CDx coverage includes METex14 splicing mutations in NSCLC in addition to pan-tumor comprehensive genomic profiling and provides highly actionable and quick therapy guidance. Coverage also includes 29 genes, including EGFR, KRAS, BRAF, ERBB2/HER2, ESR1, FGFR1, KRAS, NRAS and PIK3CA genes, plus additional key biomarkers to advance precision oncology by providing broader therapy options and optimal clinical trial enrollment. The panel is validated for use on Illumina® MiSeqDx and Illumina NextSeq 550Dx sequencers. It is powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry for confident variant calling, even at low allele frequencies.
Content meets ESMO and country-specific guidelines
Reliable Results You Can Trust
High sensitivity and specificity even with limited sample input and low allele frequency.
Scalable and Flexible
Adaptable to flexible laboratory throughput and validated on MiseqDx and NextSeq 550Dx instruments.
Comprehensive and actionable information
Can be used in parallel with tissue profiling to provide a broader picture of tumor heterogeneity, or as a quicker testing option while tissue biopsy is being obtained or if tissue is unavailable.
Number of Reads per Library
MiSeqDx: 4-6 M, NextSeq 550 Dx: 4-6 M
Library prep ~2.5 hrs; sequencing ~1 hr
Results on day 4, starting with extracted nucleic acid
MiSeqDx or NextSeq 550Dx
* Included in international and or local guidelines for NSCLC